NEW YORK, April 23, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Aetna Inc. (NYSE: AET), Abbott Laboratories (NYSE: ABT), Amgen Inc. (NASDAQ: AMGN) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1477-100free.
--
Allergan Inc. Analyst Notes
On April 17, 2014, Allergan Inc.'s (Allergan) stock moved up 1.87% higher to end the trading session at $133.92, outperforming the S&P 500 Index that moved up 0.14% over the same day. Shares in Allergan opened the session at $130.38 and oscillated in the range of $129.20 - $134.41, thereby creating a 52-week high of $134.41. Over the past three months, the stock has returned 11.46% outperforming the S&P 500 Index, which advanced 1.42% over the same time period. The Company will report its Q1 2014 earnings on May 7, 2014. The full analyst notes on Allergan are availabletodownload free of charge at:
http://www.analystsreview.com/1477-AGN-23Apr2014.pdf
--
Aetna Inc. Analyst Notes
On April 11, 2014, Aetna Inc. (Aetna) along with Tenet's Baptist Health System (Baptist) and HealthTexas Medical Group (HealthTexas) announced an accountable care collaboration along with the introduction of the Aetna Whole Health product in the San Antonio area. The Company stated that Aetna Whole Health is a collection of benefits plans that will provide its members with highly coordinated care from physicians and facilities in the Baptist and the HealthTexas. Further, the health plans are made for fully insured customers with employees who live or work in Bexar, Guadalupe, Comal and Kendall counties. According to Aetna, the products will be available on July 1, 2014. Baptist and HealthTexas will operate through five hospitals, 42 primary care offices and more than 900 physicians in the San Antonio area. The full analyst notes onAetnaare availabletodownload free of charge at:
http://www.analystsreview.com/1477-AET-23Apr2014.pdf
--
Abbott Laboratories Analyst Notes
On April 16, 2014, Abbott Laboratories (Abbott) released its Q1 2014 earnings. The Company reported Q1 2014 net sales of $5.2 billion, down 2.5% YoY, which includes 3.0% negative impact of foreign exchange. During the quarter, the Company's international sales declined 2.3% YoY to $3.8 billion. According to the Company, the August 2013 sales disruption in International Nutrition and the timing of supply of key products in Established Pharmaceuticals, primarily related to an expected plant shutdown for capacity expansion purposes, are estimated to have reduced Abbott's international sales growth by approximately 2.6 percentage points. The Company's Q1 2014 net earnings came in at $375 million or $0.24 per diluted share, compared to net income of $544 million or $0.34 per diluted share in Q1 2013. For 2014, the Company expects EPS from continuing operations under GAAP between $1.13 and $1.23. The full analyst notes on Abbott are availabletodownload free of charge at:
http://www.analystsreview.com/1477-ABT-23Apr2014.pdf
--
Amgen Inc. Analyst Notes
On April 17, 2014, Amgen Inc. (Amgen) announced that the Company plans to release its Q1 2014 earnings on April 22, 2014, after market close. The earnings release will be followed by a conference call at 2:15 PDT to discuss the financial results and business outlook. The Company's Chairman and CEO, Robert A. Bradway, and other members of senior management team will participate in the call. According to Zacks Investment research data, the consensus EPS forecast for Q1 2014 is $1.81. The full analyst notes on Amgen are availabletodownload free of charge at:
http://www.analystsreview.com/1477-AMGN-23Apr2014.pdf
--
Medtronic Inc. Analyst Notes
On April 21, 2014, Medtronic Inc. (Medtronic) issued a statement in relation to a recent ruling by Federal District Court of Delaware. The ruling granted in part Edwards Lifesciences a preliminary injunction that prevents Medtronic from selling or offering to sell its CoreValve® System in the U.S., except through a mechanism that Medtronic is pursuing with Edwards Lifesciences that would allow currently trained sites to treat patients with CoreValve based on a physician's medical judgment. The injunction will go into effect on April 23, 2014. In addition, Medtronic has asked the U.S. Circuit Court of Appeals to postpone the injunction until it can determine if the injunction was properly issued. Medtronic has also urged the Court for an expedited appeal of the injunction ruling, and other underlying legal issues, with the last appeal brief to be submitted by June 19, 2014. The court has acceded to Medtronic's request. The full analyst notes on Medtronic are availabletodownload free of charge at:
http://www.analystsreview.com/1477-MDT-23Apr2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
